MedTrace Logo

Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

NCT01832285 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-04-23

No results posted yet for this study

Summary

The purpose of this study is to determine effect of Fluvoxamine augmentation on cognitive function , aggressive behavior , clinical symptoms and mRNA (messenger ribonucleic acid) and protein expression in human peripheral mononuclear blood cells (PMC) in medicated schizophrenia patients

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Interventions

DRUG

fluvoxamine

100mg/day, PO(in the mouth) each day during 6 weeks

Sponsors & Collaborators

  • Sha'ar Menashe Mental Health Center

    lead OTHER

Principal Investigators

  • Silver Henry, Professor · Shaar Menashe Mental Health Center Affilated to Medical Faculty of Technion University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832285 on ClinicalTrials.gov